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Pre-ESRD Depression and Post-ESRD Mortality in
Patients with Advanced CKD Transitioning to Dialysis
Miklos Z. Molnar,*† Elani Streja,‡ Keiichi Sumida,* Melissa Soohoo,‡ Vanessa A. Ravel,‡ Abduzhappar Gaipov,*§
Praveen K. Potukuchi,* Fridtjof Thomas,| Connie M. Rhee,‡ Jun Ling Lu,* Kamyar Kalantar-Zadeh,‡ and
Csaba P. Kovesdy*¶
Abstract
Background and objectives Depression in patients with nondialysis-dependent CKD is often undiagnosed,
empirically overlooked, and associated with higher risk of death, progression to ESRD, and hospitalization.
However, there is a paucity of evidence on the association between the presence of depression in patients with
advanced nondialysis-dependent CKD and post-ESRD mortality, particularly among those in the transition
period from late-stage nondialysis-dependent CKD to maintenance dialysis.
Design, setting, participants, & measurements From a nation-wide cohort of 45,076 United States veterans who
transitioned to ESRD over 4 contemporary years (November of 2007 to September of 2011), we identiﬁed 10,454
(23%) patients with a depression diagnosis during the predialysis period. We examined the association of pre-
ESRD depression with all-cause mortality after transition to dialysis using Cox proportional hazards models
adjusted for sociodemographics, comorbidities, and medications.
Results Patients were 72611 years old (mean6SD) and included 95% men, 66% patients with diabetes, and 23%
blacks. The crudemortality rate was similar in patients with depression (289/1000 patient-years; 95% conﬁdence
interval, 282 to 297) versus patients without depression (286/1000 patient-years; 95% conﬁdence interval, 282 to
290). Compared with patients without depression, patients with depression had a 6% higher all-cause mortality
risk in the adjusted model (hazard ratio, 1.06; 95% conﬁdence interval, 1.03 to 1.09). Similar results were found
across all selected subgroups as well as in sensitivity analyses using alternate deﬁnitions of depression.
Conclusion Pre-ESRD depression has a weak association with post-ESRD mortality in veterans transitioning to
dialysis.
Clin J Am Soc Nephrol 12: 1428–1437, 2017. doi: https://doi.org/10.2215/CJN.00570117
Introduction
Previous studies have indicated that approximately
20%–40% of patients with nondialysis-dependent CKD
(NDD-CKD) as well as patients on maintenance dialysis
and kidney transplant recipients suffer from depression
(1–6). Depression is known to negatively and severely
affect patients’ quality of life (7,8), and has also been
associated with higher rates of hospitalization (9–12)
and mortality (9,13,14) in patients with NDD-CKD,
patients on dialysis, and patients with kidney trans-
plants (15). In a cohort of 568 patients with NDD-CKD
in Taiwan, Tsai et al. (16) showed that the presence
of depression is associated with a higher risk of death,
a faster progression to ESRD, a faster time to ﬁrst
hospitalization, and a more rapid decline in eGFR.
We previously showed strong association between
presence of depression and antidepressant use and
higher mortality risk in almost 600,000 patients with
NDD-CKD (17). In addition, we recently also showed
that depression was associated with a higher risk of
incident NDD-CKD as well as a higher risk of incident
cardiovascular disease in a cohort of .900,000 diabetic
United States veterans without NDD-CKD at baseline
(18). Furthermore, a recent meta-analysis, which in-
cluded over 80,000 patients with NDD-CKD, conﬁrmed
the association between the presence of depression
and a higher risk of death in patients with NDD-CKD
(19). However, the association between depression in
patients with advanced NDD-CKD and mortality out-
comes post-ESRD is still unknown. To address this
knowledge gap, we aimed to investigate the association
of depression in the pre-ESRD transition period with
post-ESRD all-cause mortality using a large nationally
representative cohort of United States veterans with
advanced NDD-CKD transitioning to RRT. We hypoth-
esized that the presence of depression in patients before
transition is associated with higher risk of death after
transition to ESRD.
Materials and Methods
Study Population
We analyzed longitudinal data from the Transition
of Care in CKD Study, a retrospective cohort study
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examining United States veterans with late-stage NDD-
CKD transitioning to RRT from October 1, 2007 to Sep-
tember 30, 2011 (20–22). A total of 52,172 United States
veterans were identiﬁed from the US Renal Data System
(USRDS) as a source population. Only individuals who
transitioned to receive RRT were included in the source
population. The algorithm for the cohort deﬁnition is
shown in Figure 1. We excluded patients without any
available information on comorbid conditions, including
depression diagnoses (n=6083). We also excluded those
who were missing follow-up data (n=1013 who died or
received a kidney transplant on the date of transition to
ESRD), resulting in a study population of 45,076 patients.
Exposure Variable
We used the validated algorithm described by Frayne
et al. (23) to deﬁne depression using outpatient or inpatient
medical record before transition to dialysis. In sensitivity
analyses, we also examined associations according to
depression deﬁned by Frayne et al. (23) for depression
and/or being on antidepressant medication(s) 6 months
before transition to ESRD (baseline). Because antidepres-
sant medications often have other indications, such as pain
syndrome and post-traumatic stress disorders, we used the
deﬁnition solely on the basis of the algorithm of Frayne
et al. (23) for our main analysis. In a second sensitivity
analysis, we examined the combined effect of both having a
depression diagnosis according to Frayne et al. (23) and
using antidepressant medications (Supplemental Table 1)
by creating three groups of exposure as follows: absence of
depression (no diagnosis and not on medication), depression
with absence of pharmacotherapy (has diagnosis and not on
medication), and depression treated with pharmacotherapy
(has diagnosis and on medication or no diagnosis and on
medication).
Covariates
Data from the USRDS Patient and Medical Evidence ﬁles
were used to determine patients’ baseline demographic
characteristics and type of vascular access at the time of
dialysis initiation. Information on comorbidities at the time
of dialysis initiation was extracted from the Veterans
Affairs (VA) Inpatient and Outpatient Medical SAS Data-
sets using the International Classiﬁcation of Diseases,
Ninth Revision, Clinical Modiﬁcation (ICD-9-CM) diag-
nostic and Current Procedural Terminology codes as well
as from the VA/Centers for Medicare and Medicaid
Services data. Medication data were collected from both
the Centers for Medicare and Medicaid Services Data
(Medicare Part D) and the VA pharmacy dispensation
records. Patients who received at least one dispensation of
medications within the 6-month predialysis period imme-
diately preceding ESRD transition were recorded as having
been treated with these medications. Cardiovascular med-
ication adherence was deﬁned as the proportion of days
covered by a drug during the 6-month predialysis period
capped at 100% (22). Laboratory data were obtained from
the VA research databases as previously described (24,25),
and their baseline values were deﬁned as the average of
each covariate during the 6-month predialysis period pre-
ceding dialysis initiation. eGFR was calculated by the CKD
Epidemiology Collaboration equation (26).
Outcome Assessment
The primary outcome of interest was all-cause mortality
after dialysis initiation. All-cause mortality data, censoring
events, and associated dates were obtained from the VA
and the USRDS data sources. The start of the follow-up
period was the date of dialysis initiation, and patients were
followed up until death or other censoring events, includ-
ing kidney transplantation, loss to follow-up, or end of the
follow-up period (3, 6, and 12 months after dialysis ini-
tiation or December 27, 2012 for the entire follow-up period)
(20–22). The primary analysis used the entire follow-up
time.
Statistical Analyses
Baseline patient characteristics were summarized ac-
cording to the presence or absence of depression before
ESRD and presented as percentage for categorical variables
and mean6SD for continuous variables. Differences be-
tween categories were assessed using t tests and chi-
squared tests for continuous and categorical variables,
respectively.
The association between the presence of depression and
mortality was estimated using the Kaplan–Meier method
and Cox proportional hazards models. Models were in-
crementally adjusted for the following potential con-
founders on the basis of theoretical considerations and
their availability in this study: unadjusted; model 1 ad-
justed for age, sex, race/ethnicity, and marital status;
model 2 additionally accounted for comorbidities (demen-
tia, myocardial infarction, congestive heart failure, peri-
pheral vascular disease, connective tissue disease, lungFigure 1. | Flow chart of the study population.
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disease, peptic ulcer disease, HIV, diabetes mellitus,
stroke/paraplegia, liver disease, malignancy, and hyper-
tension), type of vascular access (arteriovenous ﬁstula,
arteriovenous graft, or catheter), eGFR slope before ESRD
initiation, post-traumatic stress disorder, substance abuse,
and numbers of mental health care and emergency de-
partment visits in the last year; model 3 (main model)
additionally accounted for medications (phosphorous
binder, active vitamin D, angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers, bicarbonate,
b-blockers, calcium channel blockers, vasodilators, di-
uretics, statins, and erythropoietin stimulating agents);
and model 4 additionally accounted for blood hemoglobin,
serum albumin, income, and cardiovascular medication
adherence.
We conducted several sensitivity analyses to evaluate the
robustness of our main ﬁndings. To compare the effect of
depression on outcomes during different follow-up pe-
riods, we repeated our analyses separately using additional
short-term deﬁnitions (3, 6, and 12 post-transition months).
The associations of depression with outcomes were
examined in subgroups of patients stratiﬁed by sex, age,
race, marital status, and presence/absence of select comor-
bidities using multivariable adjusted model 3. Potential
interactions were formally tested by including relevant
interaction terms.
Of the 45,076 patients in our study population, 41,582
(92%) had complete data available for the main adjusted
multivariable model (model 3). Because it is possible that
missingness was not at random and that the proportion of
patients with missingness was acceptable in our main
analyses, imputation was not used. We used only these
patients with complete cases in our unadjusted model as
well as our models 1 and 2;.50% of the laboratory markers
were missing (Supplemental Table 2), and therefore, model
4 was performed as an additional sensitivity analysis.
However, we also performed sensitivity analysis using
multiple imputation procedures. Missing values were
replaced by multiple imputations with a multivariate
normal regression method with data augmentation by an
iterative Markov chain Monte Carlo procedure (27,28).
Five imputed datasets were generated; primary analyses
were performed on each imputed dataset, and the com-
bination rules of Rubin (29) were used to form one set of
results.
Reported P values were two sided and reported as
signiﬁcant at ,0.05 for all analyses. All analyses were
conducted using STATA/MP, Version 14 (StataCorp,
College Station, TX). The study was approved by the
institutional review boards of the Memphis and Long
Beach VA Medical Centers, with exemption from informed
consent.
Results
Baseline Characteristics
Patients’ baseline characteristics in the overall cohort and
stratiﬁed by the depression status are presented in Table 1.
The overall mean6SD age at baseline was 72611 years old;
95% were men, 23% were black, and 66% were diabetic. The
mean6SD of the last measured eGFR before ESRD initia-
tion was 23619 ml/min per 1.73 m2. We identiﬁed 10,454
(23%) patients with depression. The median time from the
last ICD-9-CM code and initiation to the dialysis was 355
days (interquartile range, 90–973 days). Compared with
patients without a depression diagnosis, those with de-
pression were younger, were more likely to be women and
black, and had a higher prevalence of myocardial infarction,
diabetes, cerebrovascular disease, peripheral vascular dis-
ease, dementia, and peptic ulcer disease at baseline. They
were also more likely to use antidepressant medications
within 6 months before transition and less likely to use
statins and antihypertensive medications. The available
baseline laboratory parameters were clinically similar in
patients with and without depression.
Association of Pre-ESRD Presence of Depression with Post-
ESRD All-Cause Mortality in the Entire Follow-Up Period
after Dialysis Initiation
During the entire follow-up period after dialysis
initiation, a total of 25,901 (57%) all-cause deaths occurred
(crude incidence rate, 287/1000 patient-years; 95% conﬁ-
dence interval [95% CI], 283 to 290). The crude mortality
rate was similar in patients with depression (5953 [57%]
deaths; 289/1000 patient-years; 95% CI, 282 to 297) versus
patients without depression (19,948 [58%] deaths; 286/1000
patient-years; 95% CI, 282 to 290) as shown in the Kaplan–
Meier survival curve in Figure 2A. Compared with patients
without a depression diagnosis, patients with depression
had similar mortality risk in the unadjusted model (hazard
ratio [HR], 1.00; 95% CI, 0.97 to 1.03). On further adjust-
ment for sociodemographics, comorbidities, and medica-
tions, patients with depression had 6% higher mortality
risk (HR, 1.06; 95% CI, 1.03 to 1.09) (Table 2). A similar
result was found after further adjustment for laboratory
parameters and a marker of adherence (model 4) (Table 2).
In subgroup analyses, compared with patients without
depression, patients with depression had higher all-cause
mortality risk overall and across almost all subgroups
(Figure 3). Statistically signiﬁcant interactions were present
for age and cancer, with stronger associations between
depression and all-cause mortality risk among younger
patients and those without cancer.
Different results were observed in sensitivity analysis
when antidepressant medication was taken into account in
the deﬁnition of depression (Figure 2B). Compared with
patients without a depression diagnosis, patients with
depression had higher mortality risk in the unadjusted
model. Moreover, compared with those without depres-
sion, patients with depression had a 10% higher mortality
risk in the main multivariable adjusted model (model 3;
HR, 1.10; 95% CI, 1.07 to 1.13) (Table 2). Finally, depression
was associated with higher mortality risk in both the
presence and absence of pharmacotherapy (Figure 2C).
Compared with patients without depression (neither di-
agnosis nor antidepressant treatment), patients with de-
pression treated with pharmacotherapy had a 14% higher
multivariable adjusted mortality risk (HR, 1.14; 95% CI,
1.11 to 1.18), whereas patients with depression in the
absence of pharmacotherapy had a 4% higher multivariable
adjusted mortality risk (HR, 1.04; 95% CI, 1.00 to 1.09)
(Table 2). Results did not differ when multiple imputations
were used (HR, 1.06; 95% CI, 1.03 to 1.09).
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Association of Pre-ESRD Presence of Depression with Post-
ESRD All-Cause Mortality in the 3, 6, and 12 Months after
Dialysis Initiation
Supplemental Figure 1 shows the association be-
tween presence of depression and 12 months all-cause
mortality using the three deﬁnitions of depression. Com-
pared with those without a depression diagnosis, pa-
tients with depression had a nominally higher mortal-
ity risk in the adjusted model, which did not reach
statistical signiﬁcance (HR, 1.02; 95% CI, 0.98 to 1.07)
(Supplemental Table 3). Qualitatively similar results
were found in short-term follow-up periods, such as 3
Table 1. Baseline patient characteristics overall and according to pre-ESRD presence of depression
Total Cohort n=45,076
Depression on the Basis of Only Algorithm
No, n=34,622 Yes, n=10,454
Age, yr 72611 72611 68611
Men, % 95 95 94
Black race, % 23 23 25
Marital status, married, % 58 59 52
Body mass index, kg/m2 29.966.6 29.666.4 30.467.0
Vascular access type, catheter, % 78 78 78
Comorbid conditions, %
Myocardial infarction 29 28 32
Congestive heart failure 58 56 62
Peripheral vascular disease 40 39 45
Cerebrovascular disease 32 29 38
Dementia 3 2 6
Chronic obstructive pulmonary disease 45 42 54
Rheumatic disease 5 4 6
Peptic ulcer disease 8 8 10
Hemiplegia 4 3 6
HIV/AIDS ,1 ,1 ,1
Diabetes mellitus 66 63 74
Liver disease 12 10 18
Cancera 26 26 25
Hypertension 45 46 44
Medications, %
ACEIs/ARBs 35 33 41
Antidepressants 20 10 52
b-Blockers 53 50 63
Calcium channel blockers 47 44 56
Diuretics 56 53 65
Statins 47 44 55
Vasodilators 3 3 4
Vitamin D analogs 22 21 25
ESAs 17 15 23
Laboratory parameters
Serum albumin, g/dl 3.360.6 3.360.6 3.260.6
Serum AST, U/La 26639 26642 26630
Serum ALT, U/La 24634 23633 24626
Serum BUN, mg/dl 61623 62623 58621
Serum creatinine, mg/dl 4.662.4 4.762.5 4.562.2
First eGFR in the cohort, ml/min per 1.73 m2 44624 41623 50626
Last eGFR before ESRD,a ml/min per 1.73 m2 23619 23619 23620
Serum phosphorus, mg/dl 5.161.3 5.161.3 5.061.2
Serum calcium, mg/dl 8.860.7 8.860.8 8.760.7
Alkaline phosphatase, IU/L 98666 97666 102661
Blood hemoglobin, g/dla 10.361.5 10.361.5 10.461.5
Serum bicarbonate, mg/dla 2364 2364 2364
Cholesterol, mg/dl 155650 153649 158651
Serum potassium, mEq/L 4.560.6 4.560.6 4.560.5
WBC, 109/L 863 863 863
Data are presented as number (percentage) or mean6SD. All laboratory results were averaged over the 6-month predialysis period.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ESA, erythropoietin stimulating agent; AST, as-
partate aminotransferase; ALT, alanine aminotransferase; WBC, white blood cell.
aNo statistically signiﬁcant difference between patients with and without depression.
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Figure 2. | Probability of all-causemortality of patients with andwithout depression using different definitions of depression. (A) Depression
defined only using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code is not associated
with mortality. (B) Depression defined on the basis of the ICD-9-CM code and/or antidepressant medication, or on the basis of the ICD-9-CM
code and/or antidepressant medication separated by treatment (C) is associated with higher mortality.
1432 Clinical Journal of the American Society of Nephrology
T
ab
le
2
.
A
d
ju
st
ed
h
az
ar
d
ra
ti
o
s
(9
5
%
co
n
fi
d
en
ce
in
te
rv
al
s)
fo
r
al
l-
ca
u
se
m
o
rt
al
it
y
in
it
ia
ti
o
n
u
si
n
g
d
if
fe
re
n
t
d
efi
n
it
io
n
s
o
f
d
ep
re
ss
io
n
D
eﬁ
ni
ti
on
of
D
ep
re
ss
io
n
O
n
th
e
B
as
is
of
A
lg
or
it
hm
(M
ai
n
M
od
el
)
O
n
th
e
B
as
is
of
A
lg
or
it
hm
an
d
/
or
A
nt
id
ep
re
ss
an
tM
ed
ic
at
io
n
O
n
th
e
B
as
is
of
A
lg
or
it
hm
an
d
/
or
A
nt
id
ep
re
ss
an
tM
ed
ic
at
io
n
A
bs
en
ce
of
D
ep
re
ss
io
n
Pr
es
en
ce
of
D
ep
re
ss
io
n
A
bs
en
ce
of
D
ep
re
ss
io
n
Pr
es
en
ce
of
D
ep
re
ss
io
n
A
bs
en
ce
of
D
ep
re
ss
io
n
D
ep
re
ss
io
n
w
it
h
A
bs
en
ce
of
Ph
ar
m
ac
ot
he
ra
py
D
ep
re
ss
io
n
Tr
ea
te
d
w
ith
Ph
ar
m
ac
ot
he
ra
py
Pa
ti
en
ts
34
,6
22
10
,4
54
31
,1
35
13
,9
41
31
,1
35
50
00
89
41
E
ve
nt
s
19
,9
48
(5
8)
59
53
(5
7)
17
,7
11
(5
7)
81
90
(5
9)
17
,7
11
(5
7)
27
98
(5
6)
53
92
(6
0)
C
ru
d
e
in
ci
d
en
t
ra
te
28
6
(2
82
to
29
0)
28
9
(2
82
to
29
7)
28
0
(2
76
to
28
4)
30
2
(2
96
to
30
9)
28
0
(2
76
to
28
4)
28
3
(2
73
to
29
4)
31
3
(3
04
to
32
1)
U
na
d
ju
st
ed
,
n=
41
,5
82
1
(R
ef
er
en
ce
)
1.
00
(0
.9
7
to
1.
03
)
1
(R
ef
er
en
ce
)
1.
06
(1
.0
4
to
1.
09
)
1
(R
ef
er
en
ce
)
1.
00
(0
.9
7
to
1.
06
)
1.
10
(1
.0
6
to
1.
13
)
M
od
el
1,
n=
41
,5
82
1
(R
ef
er
en
ce
)
1.
20
(1
.1
7
to
1.
24
)
1
(R
ef
er
en
ce
)
1.
24
(1
.2
1
to
1.
28
)
1
(R
ef
er
en
ce
)
1.
18
(1
.1
3
to
1.
23
)
1.
29
(1
.2
5
to
1.
33
)
M
od
el
2,
n=
41
,5
82
1
(R
ef
er
en
ce
)
1.
04
(1
.0
1
to
1.
07
)
1
(R
ef
er
en
ce
)
1.
06
(1
.0
3
to
1.
09
)
1
(R
ef
er
en
ce
)
1.
04
(1
.0
0
to
1.
09
)
1.
07
(1
.0
4
to
1.
11
)
M
od
el
3,
n=
41
,5
82
1
(R
ef
er
en
ce
)
1.
06
(1
.0
3
to
1.
09
)
1
(R
ef
er
en
ce
)
1.
10
(1
.0
7
to
1.
13
)
1
(R
ef
er
en
ce
)
1.
03
(0
.9
9
to
1.
07
)
1.
14
(1
.1
1
to
1.
18
)
M
od
el
4,
n=
20
,5
42
1
(R
ef
er
en
ce
)
1.
08
(1
.0
3
to
1.
13
)
1
(R
ef
er
en
ce
)
1.
12
(1
.0
7
to
1.
16
)
1
(R
ef
er
en
ce
)
1.
06
(0
.9
9
to
1.
13
)
1.
14
(1
.0
9
to
1.
19
)
D
at
a
ar
e
pr
es
en
te
d
as
nu
m
be
r
(p
er
ce
nt
ag
e)
or
ha
za
rd
ra
ti
o
(9
5%
co
nﬁ
d
en
ce
in
te
rv
al
)u
nl
es
s
ot
he
rw
is
e
sp
ec
iﬁ
ed
.T
he
cr
ud
e
in
ci
d
en
tr
at
e
pr
es
en
te
d
is
in
pe
r
10
00
pa
ti
en
t-
ye
ar
s.
M
od
el
s
ar
e
as
fo
llo
w
s.
U
na
d
ju
st
ed
m
od
el
:o
nl
y
ex
po
su
re
va
ri
ab
le
in
cl
ud
ed
.M
od
el
1
ad
ju
st
ed
fo
r
ag
e,
se
x,
ra
ce
/
et
hn
ic
it
y,
an
d
m
ar
it
al
st
at
us
.M
od
el
2
ad
d
it
io
na
lly
ac
co
un
te
d
fo
r
co
m
or
bi
d
it
ie
s
(d
em
en
ti
a,
m
yo
ca
rd
ia
li
nf
ar
ct
io
n,
co
ng
es
ti
ve
he
ar
tf
ai
lu
re
,p
er
ip
he
ra
lv
as
cu
la
rd
is
ea
se
,c
on
ne
ct
iv
e
ti
ss
ue
d
is
ea
se
,l
un
g
d
is
ea
se
,p
ep
ti
c
ul
ce
rd
is
ea
se
,H
IV
,d
ia
be
te
s
m
el
lit
us
,s
tr
ok
e/
pa
ra
p
le
gi
a,
liv
er
d
is
ea
se
,
m
al
ig
na
nc
y,
an
d
hy
pe
rt
en
si
on
),
ty
pe
of
va
sc
ul
ar
ac
ce
ss
(a
rt
er
io
ve
no
us
ﬁ
st
ul
a,
ar
te
ri
ov
en
ou
sg
ra
ft
,o
rc
at
he
te
r)
,e
G
FR
sl
op
e
be
fo
re
E
SR
D
in
it
ia
ti
on
,p
os
t-
tr
au
m
at
ic
st
re
ss
d
is
or
d
er
,s
ub
st
an
ce
ab
us
e,
an
d
nu
m
be
rs
of
m
en
ta
lh
ea
lt
h
ca
re
an
d
em
er
ge
nc
y
d
ep
ar
tm
en
tv
is
it
s.
M
od
el
3
ad
d
it
io
na
lly
ac
co
un
te
d
fo
r
m
ed
ic
at
io
ns
(p
ho
sp
ho
ro
u
s
bi
nd
er
,a
ct
iv
e
vi
ta
m
in
D
,a
ng
io
te
ns
in
-c
on
ve
rt
in
g
en
zy
m
e
in
hi
bi
to
rs
/
an
gi
ot
en
si
n
re
ce
pt
or
bl
oc
ke
rs
,b
ic
ar
bo
na
te
,b
-b
lo
ck
er
s,
ca
lc
iu
m
ch
an
ne
lb
lo
ck
er
s,
va
so
d
ila
to
rs
,d
iu
re
ti
cs
,s
ta
ti
ns
,a
nd
er
yt
hr
op
oi
et
in
st
im
ul
at
in
g
ag
en
ts
).
M
od
el
4
ad
d
it
io
na
lly
ac
co
un
te
d
fo
r
bl
oo
d
he
m
og
lo
bi
n,
se
ru
m
al
bu
m
in
,i
nc
om
e,
an
d
ca
rd
io
va
sc
u
la
r
m
ed
ic
at
io
n
ad
he
re
nc
e.
Clin J Am Soc Nephrol 12: 1428–1437, September, 2017 Pre-ESRD Depression and Post-ESRD Mortality, Molnar et al. 1433
(Supplemental Table 4) and 6 months (Supplemental
Table 5).
Discussion
In this large national cohort of United States veterans
with late-stage NDD-CKD transitioning to dialysis, we
found a weak association between pre-ESRD diagnosis of
depression and all-cause mortality after dialysis initiation,
independent of demographics, comorbidities, medications,
and type of vascular access.
Several previous studies indicated strong associations
between depression and higher risk of mortality in patients
with kidney disease (15,17,18,30–34) and patients without
kidney disease (35). However, the most recent analyses
showed associations only between moderate and severe
symptoms (Beck Depression Inventory .19) of depression
and mortality in patients with ESRD (36). The underlying
mechanisms linking depression to higher risk of mortality
are likely to be multifactorial. Comorbid depression was
shown to impair the ability to perform self-care in patients
with diabetes (37), and it is also reportedly associated with
obesity, persistence of smoking, and lack of physical
exercise (38–40). Depression is also strongly associated
with medication nonadherence, which has been shown to
be an independent predictor of mortality after dialysis
initiation (22). In our sensitivity analysis, we did adjust for
medication nonadherence, and the association remained
signiﬁcant, which indicates that there are other mecha-
nisms that may explain this association. These explanations
may include a higher level of low-grade systemic inﬂam-
mation, activation of the hypothalamic-pituitary-adrenal
axis (increased cortisol secretion), and activation of the
sympathetic nervous system, which have all been fre-
quently reported in association with depression (41–43).
In an earlier study, we also showed that the presence of
depression is associated with severity of inﬂammation in
prevalent kidney transplant recipients (44). Moreover, the
presence of depression is also associated with less adher-
ence with ﬂuid restriction in patients on dialysis (45).
Another potential explanation is that more severe symp-
toms of depression may develop as a result of a greater
Figure 3. | Patients with depression experienced higher all-cause mortality risk across most examined subgroups. Model is adjusted for
age, sex, race/ethnicity, marital status, comorbidities (dementia, myocardial infarction, congestive heart failure, peripheral vascular disease,
connective tissue disease, lung disease, peptic ulcer disease, HIV, diabetes mellitus, stroke/paraplegia, liver disease, malignancy, and hy-
pertension), type of vascular access (arteriovenous fistula, arteriovenous graft, or catheter), eGFR slope before ESRD initiation, post-traumatic
stress disorder, substance abuse, numbers ofmental health care and emergency department visits, andmedications (phosphorous binder, active
vitamin D, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, bicarbonate, b-blockers, calcium channel blockers,
vasodilators, diuretics, statins, and erythropoietin stimulating agents). CHF, congestive heart failure; CVD, cerebrovascular disease.
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disease burden, and therefore, depression could be a
mediator of the association between comorbid conditions
and mortality (46). The converse can also be true, with
depression resulting in more severe comorbidity, such as
malnutrition due to anorexia, with these comorbidities
mediating the relationship between depression and mor-
tality (44,46).
Regardless of the underlying mechanisms, the associa-
tion between depression and mortality in patients with
NDD-CKD is clinically important, because it points to the
possibility of improving outcomes through appropriate
and successful management of depression. Antidepressant
medication is only one treatment of choice for these
patients. We did not ﬁnd clinically signiﬁcant survival
difference between patients in the absence or presence of
pharmacotherapy. This ﬁnding is seemingly unexpected;
however, we do not have data about antidepressant
medication adherence of these patients, and we could
not ascertain the successfulness of the applied antidepres-
sant medications in alleviating depression. In addition,
there are other, potentially more effective treatment options
for depression in patients with CKD, such as cognitive
behavioral therapy, for which data were not available for
this analysis. Cukor et al. (47) performed a small random-
ized, controlled trial, which indicated that cognitive behav-
ioral therapy led to signiﬁcant improvement in depression
symptoms as well as medication adherence in patients with
ESRD. Exercise training program is also a potential treat-
ment for patients with depression (48).
One signiﬁcant challenge in everyday clinical practice is
the recognition of depression in patients with NDD-CKD.
The main reason why physicians may fail to recognize
depressive symptoms is related to the considerable overlap
between somatic depressive symptoms and the burden of
uremic symptoms of patients with NDD-CKD, such as
sleep disturbance, lack of energy, decreased appetite, and
concentrating difﬁculties (34,49). A multidisciplinary ap-
proach for recognizing and treating depression has shown
promising results in patients with coronary artery disease
(50) and could be considered in patients with NDD-CKD.
Our study is notable for its large sample size and event
numbers and being representative of veterans who re-
ceived care in the VA system across the entire United
States. In addition, we used a validated method to make the
depression diagnosis using an administrative dataset (23).
To our knowledge, this is the ﬁrst study to assess the
associations between a diagnosis of comorbid depression
before dialysis initiation and all-cause mortality after
dialysis initiation.
This study also has several limitations that need to be
acknowledged. First, because this was an observational
study, only associations, but no cause-effect relationships,
can be established. Second, most of our patients were men
who were United States veterans; hence, the results may
not be generalizable to women or other patient popula-
tions, in particular those outside the United States. Third,
our study is also limited by the use of an administrative
database and antidepressants to deﬁne depression. How-
ever, the signiﬁcant correlates of baseline depression in our
study were similar to those found in previous studies. In
addition, some antidepressants may have been prescribed
for diagnoses other than depression. However, we used
only the deﬁnition on the basis of algorithm of Frayne
et al. (23) as our main analysis to eliminate this potential
bias. We did not have access to metrics quantifying the
success rate of depression therapy; hence, we cannot
determine if successful management of depression over
time might alleviate some of the observed adverse effects.
Moreover, there was a signiﬁcant amount of missing
laboratory data. However, the results remained qualita-
tively similar after multiple imputations in our ﬁnal
model. Finally, as with all observational studies, we were
not able to eliminate the possibility of unmeasured
confounders, such as proteinuria.
In conclusion, in this large national cohort of United
States veterans with late-stage NDD-CKD transitioning to
dialysis, we found an independent but weak association
between pre-ESRD diagnosis of depression and all-cause
mortality after dialysis initiation. Depression may be a
potential modiﬁable factor before and after dialysis initi-
ation. Although pre-ESRD treatment of depression may
still be warranted to improve patients’ quality of life, such
treatment may not have a beneﬁt on post-ESRD mortality.
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